Elan Shares Climb on $3.25B Biogen's Tysabri Deal
Feb. 6 (Bloomberg) -- Bloomberg's Caroline Hyde reports on what is next for Elan Corp. as Biogen Idec Inc. agreed to acquire the company's stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties. She speaks on Bloomberg Television's "The Pulse."
Most Recent Videos
China Returns to U.S. IPO Market in a Big Way
37:32 - Tom Farley, president at the NYSE Group, discusses the timing of the ZTO Express debut, listing in New York versus China and the outlook for the IPO market in the U.S. He speaks to Bloomberg's Haidi Lun on "Bloomberg Markets." (Source: Bloomberg)